Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre E C
Service de Neurologie, Cliniques Universitaires Saint-Luc, Université de Louvain, Brussels, Belgium.
Muscle Nerve. 1995 Jul;18(7):720-9. doi: 10.1002/mus.880180708.
We report the results of botulinum toxin type A (Dysport, Porton Products, UK) treatment over 5 years in 107 patients with blepharospasm, Meige's syndrome, oromandibular dystonia, hemifacial spasm, cervical dystonia, and writer's cramp. Electromyography was used to localize dystonic muscles and guide Dysport injections in Meige's syndrome, oromandibular dystonia, cervical dystonia, and writer's cramp. All but 2 Meige's syndrome and 2 writer's cramp patients responded to treatment. Improvement was dramatic in blepharospasm (79%) and hemifacial spasm (90%); pronounced in cervical dystonia (74%); and moderate in Meige's syndrome (53%), oromandibular dystonia (57%), and writer's cramp (34%). Although Dysport doses were 50-75% lower than usually reported, response and improvement rates as well as relapse intervals were similar to those of others. To treat cervical dystonia relapses, only 50% of the initial dose was required for continued optimal relief of symptoms. Low-dose Dysport was associated with a very low incidence of dysphagia in cervical dystonia.
我们报告了107例患有眼睑痉挛、梅杰综合征、口下颌肌张力障碍、偏侧面肌痉挛、颈部肌张力障碍和书写痉挛的患者接受A型肉毒毒素（英国Porton Products公司的Dysport）治疗5年的结果。在梅杰综合征、口下颌肌张力障碍、颈部肌张力障碍和书写痉挛患者中，使用肌电图来定位肌张力障碍肌肉并指导Dysport注射。除2例梅杰综合征患者和2例书写痉挛患者外，所有患者对治疗均有反应。眼睑痉挛（79%）和偏侧面肌痉挛（90%）的改善显著；颈部肌张力障碍（74%）改善明显；梅杰综合征（53%）、口下颌肌张力障碍（57%）和书写痉挛（34%）改善程度中等。尽管Dysport剂量比通常报道的低50 - 75%，但反应率、改善率以及复发间隔与其他研究相似。为治疗颈部肌张力障碍复发，仅需初始剂量的50%即可持续最佳缓解症状。低剂量Dysport与颈部肌张力障碍患者吞咽困难的发生率极低相关。
